Dexcom reported Q1 revenue $1.19 bn, up 15% YoY, beating consensus $1.18 bn.
Adjusted earnings rose to 56 cents per share, surpassing analysts’ 47‑cent estimate.
Shares slipped 4.3% in after‑hours trading despite reaffirming FY revenue guidance of $5.16‑$5.25 bn.
Company expanded U.S. launch of G7 15‑day sensor, added Stelo meal‑logging, and released data on type‑2 diabetes benefits.